ACCC | Novartis ribociclib only Category 1 preferred first-line treatment option for HR+/HER2- mBC in combination with an AI in updated NCCN Clinical Practice Guidelines in Oncology
Novartis ribociclib only Category 1 preferred first-line treatment option for HR+/HER2- mBC in combination with an AI in updated NCCN Clinical Practice Guidelines in Oncology
In Person Conference & ConventionOctober 3, 2026 at 7:30 AM EDT8787 Keystone Crossing, Indianapolis, IN, USASheraton Indianapolis Hotel at Keystone Crossing, Indianapolis
In Person Conference & ConventionOctober 15, 2026 at 5:30 PM PDT255 N Virginia St, Reno, NV, USAWhitney Peak Hotel Reno, Tapestry Collection by Hilton, Reno
